Allergy Therapeutics PLC Stock
Price
Target price
€0.13
€0.13
0.780%
0.001
0.780%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Allergy Therapeutics PLC Stock
The Allergy Therapeutics PLC stock is trending slightly upwards today, with an increase of €0.001 (0.780%) compared to yesterday's price.
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | 0.780% | 8.475% | 6.667% | 76.552% | 9.402% | 169.474% | -32.275% |
| Beximco Pharmaceuticals Ltd. GDR | - | -6.796% | 6.667% | 12.676% | 7.143% | -9.434% | -51.759% |
| Eledon Pharmaceuticals Inc. | -1.650% | -1.087% | 34.815% | -58.257% | 42.188% | -39.333% | -84.757% |
| SELLAS Life Sciences Group Inc | -7.250% | -14.981% | 41.578% | 196.959% | 17.108% | 6.959% | -27.081% |
News
Why AT&T Stock Climbed Today
Shares of AT&T (NYSE: T) popped on Wednesday after the telecommunications titan announced strong subscriber growth metrics.
By the close of trading, AT&T's stock price was up more than 4%.
Image
Stock Market Today, Jan. 28: AT&T Rises After Earnings Beat and New Buyback Plan
AT&T (NYSE:T), a provider of wireless voice and data services, broadband, and digital television, closed Wednesday at $24.08, up 4.70%. The stock moved higher after Q4 results beat EPS and revenue
Space Stock Boom: Why Retail and Wall Street Are Aligning
For the last five years, the narrative between retail and institutional investors has been one of battle. Retail traders chased hype, while institutions stuck to the numbers. Due to fundamental
